Marotta Asset Management Sells 178 Shares of Johnson & Johnson (NYSE:JNJ)

Marotta Asset Management trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 6.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,676 shares of the company’s stock after selling 178 shares during the quarter. Marotta Asset Management’s holdings in Johnson & Johnson were worth $385,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Legacy Private Trust Co. raised its position in Johnson & Johnson by 8.4% during the fourth quarter. Legacy Private Trust Co. now owns 39,173 shares of the company’s stock valued at $5,665,000 after purchasing an additional 3,047 shares during the period. Douglas Lane & Associates LLC raised its holdings in Johnson & Johnson by 1.1% during the 4th quarter. Douglas Lane & Associates LLC now owns 599,386 shares of the company’s stock valued at $86,683,000 after buying an additional 6,526 shares during the period. InvesTrust bought a new stake in Johnson & Johnson in the fourth quarter worth $6,355,000. Fulton Bank N.A. increased its position in Johnson & Johnson by 7.8% during the fourth quarter. Fulton Bank N.A. now owns 47,550 shares of the company’s stock valued at $6,877,000 after acquiring an additional 3,427 shares during the last quarter. Finally, Innova Wealth Partners purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $416,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 0.1 %

Shares of NYSE JNJ traded up $0.18 during midday trading on Friday, reaching $142.45. 1,602,368 shares of the stock were exchanged, compared to its average volume of 6,725,647. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock has a market capitalization of $342.97 billion, a P/E ratio of 20.62, a PEG ratio of 2.52 and a beta of 0.51. The company has a 50 day simple moving average of $150.03 and a 200 day simple moving average of $156.04. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.66 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on JNJ shares. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Morgan Stanley raised their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada boosted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Finally, Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.